FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

FDA Warns MAST Biosurgery Over Manufacturing Violations

FDA issues MAST Biosurgery a Warning Letter after an August inspection cited serious manufacturing quality and safety reporting violations related to ...

latest-news-card-1
Biologics

Scancell Advancing iSCIB1+ Into Phase 3 Melanoma Trial

FDA approves a Scancell Holdings IND to begin a registrational Phase 3 trial of iSCIB1+ in patients with advanced melanoma.

latest-news-card-1
Human Drugs

Former CytoDyn CEO Sentenced to Prison

A federal judge sentences former CytoDyn chief executive Nader Pourhassan to 30 months in prison for misleading investors about the development of an ...

latest-news-card-1
Human Drugs

FDA Cites Pine Pharma Over Sterility, Quality Control

FDA cites Pine Pharmaceuticals for multiple quality and sterility violations following a 10-day inspection of the companys drug outsourcing facility i...

latest-news-card-1
Human Drugs

Plausible Mechanism Drug Pathway Raises Process Concerns

A Health Affairs analysis on FDAs new pathway allowing drug approvals based on a plausible mechanism of action warns that the approach raises unresolv...

latest-news-card-1
Biologics

Sarepta Reports Positive Data on Duchenne Gene Therapy

Sarepta Therapeutics announces that its gene therapy Elevidys significantly slowed disease progression over three years in ambulatory patients with Du...

latest-news-card-1
Biologics

Advocacy Push Precedes FDA Meeting on Stalled Gene Therapy

AMT-130 is a gene therapy designed to lower levels of the mutant huntingtin protein believed to drive Huntingtons disease progression.

latest-news-card-1
FDA General

Symposium on Clinical Trials, Bioequivalence and Pharmacovigilance

U.S., U.K. and Canadian drug regulators announce a joint international symposium to discuss evolving regulatory expectations for clinical trials, bioe...

latest-news-card-1
Human Drugs

FDA Highlights Expedited Pathways in Drug Approval Report

FDAs annual report on drug approvals says the majority of novel drugs approved in 2025 moved through accelerated regulatory pathways.

latest-news-card-1
Human Drugs

Advocacy Groups Press Congress on Biosimilar Legislation

Advocacy groups urge Congress to advance legislation that would eliminate the statutory distinction between biosimilars and so-called interchangeable ...